Andy Cohen TRT: Legal and Disclosure Obligations Explained

What Andy Cohen Has Said About TRT

Andy Cohen has mentioned testosterone replacement therapy in interviews and on his radio program, framing it as part of his personal wellness routine. He described noticing changes in energy, mood, and body composition after starting the treatment. His comments reached a large audience and prompted broader public discussion about TRT as a mainstream option for middle-aged men.

The Significance of a Public Figure Speaking About TRT

Cohen is not a physician. His comments carry no clinical authority. They do, however, carry cultural weight. Research published in JAMA Internal Medicine has documented that celebrity health disclosures consistently shift public interest and screening behavior, sometimes benefiting public health and sometimes driving medically unnecessary demand for treatments [1].

His willingness to name a specific therapy publicly contributes to destigmatizing male hormone therapy. That is a measurable social effect. At the same time, it creates a responsibility gap: audiences may conflate a celebrity's anecdote with clinical recommendation.

Does Cohen Have a Legal Obligation to Disclose His TRT Use?

No. A private citizen, including a media personality discussing personal medical history, faces no federal statute requiring disclosure of hormone therapy. The Health Insurance Portability and Accountability Act (HIPAA) governs covered entities, not individuals choosing to speak publicly [2]. Cohen's voluntary disclosures are precisely that: voluntary.

The calculus changes only if Cohen were paid to promote a specific TRT product, clinic, or telehealth platform. At that point, Federal Trade Commission rules under 16 CFR Part 255 require clear and conspicuous disclosure of the material connection [3].

FTC Disclosure Rules and Paid TRT Endorsements

When a celebrity receives compensation, free product, or other material benefit in exchange for discussing a health treatment, FTC endorsement guidelines classify that speech as advertising. The rules apply regardless of whether the celebrity personally believes what they say.

What "Material Connection" Means in Practice

The FTC defines a material connection as any relationship that might affect how an audience weighs an endorsement. Cash payment is the obvious example. Free consultations, equity stakes in a telehealth company, or complimentary prescriptions may also qualify [3].

For TRT specifically, the FTC's 2023 updated guidelines (released May 2023) tightened requirements: endorsers must have substantiation for health-related claims they make, and disclosures must appear "in close proximity" to the claim, not buried in a bio or linked in a caption [3].

A violation can result in civil penalties of up to $50,120 per violation. The FTC pursued several cases against health-product influencers between 2021 and 2024, signaling active enforcement in the wellness space.

Platform-Level Rules Layer on Top

Instagram, YouTube, and TikTok each maintain independent branded content policies that may require disclosures even when the FTC threshold has not technically been met. These platform terms do not carry civil penalty risk, but violations can result in account restrictions or removal of content.

Cohen's primary platform is live television and SiriusXM radio, where FCC sponsorship identification rules also apply. Under 47 U.S.C. § 317, any broadcast mention of a product in exchange for consideration must be identified as paid content [4].

Standard TRT Protocols: What the Evidence Actually Shows

The clinical picture of TRT is more structured than any celebrity anecdote suggests. Physicians follow evidence-based protocols grounded in randomized controlled trial data and specialty society guidelines.

Diagnosis Before Treatment

The Endocrine Society's 2018 Clinical Practice Guideline specifies that testosterone deficiency should be confirmed by two separate morning serum total testosterone measurements below 300 ng/dL, combined with symptoms of hypogonadism [5]. Symptoms include reduced libido, fatigue, depressed mood, decreased lean mass, and erectile dysfunction.

The American Urological Association echoes this threshold. Both organizations caution against initiating TRT based on symptoms alone without biochemical confirmation [6].

Obtaining a single lab draw and prescribing immediately represents a deviation from standard of care. Patients should expect their clinician to order a second confirmatory test, ideally at least one week after the first, and to assess free testosterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) to distinguish primary from secondary hypogonadism.

Formulations and Dosing

Several FDA-approved delivery systems exist:

• Testosterone cypionate or enanthate (injectable): 100 to 200 mg intramuscularly every 7 to 14 days. This is the most widely used formulation in the United States due to low cost and predictable pharmacokinetics [5].
• Topical gels (AndroGel 1%, 1.62%; Testim; Vogelxo): 50 to 100 mg applied daily to shoulders or upper arms. Transfer risk to partners and children is a documented concern and an FDA-labeled warning [7].
• Transdermal patch (Androderm): 4 mg applied nightly to non-scrotal skin.
• Subcutaneous pellets (Testopel): 150 to 450 mg implanted every 3 to 6 months.
• Buccal tablet (Striant): 30 mg applied twice daily to the gum.

Injectable cypionate dominates telehealth TRT prescriptions because self-administration is straightforward and the cost can be as low as $30, $50 per month without insurance.

Monitoring on TRT

The Testosterone Trials (TTrials), a coordinated set of seven randomized placebo-controlled trials in men 65 and older (N=790), provided the most rigorous safety monitoring data available [8]. Follow-up labs included hematocrit, PSA, and cardiovascular biomarkers at 3, 6, and 12 months.

Standard clinical monitoring mirrors that design:

| Parameter | Frequency | |---|---| | Serum testosterone (trough) | 3 months after initiation, then annually | | Hematocrit | Every 3 to 6 months | | PSA | 3 to 6 months, then annually | | Lipid panel | Annually | | Bone mineral density | Every 1 to 2 years (if osteoporosis risk present) |

Hematocrit above 54% requires dose reduction or phlebotomy due to elevated thrombosis risk. PSA rise above 1.4 ng/mL over any 12-month period triggers urology referral per Endocrine Society guidance [5].

Cardiovascular Risk: What the Data Show

TRT's cardiovascular safety has been debated for over a decade. The FDA added a warning label in 2015 requiring all testosterone products to disclose the possibility of increased cardiovascular risk [7].

The TRAVERSE Trial

The TRAVERSE trial (N=5,246 men aged 45 to 80 with hypogonadism and elevated cardiovascular risk) is the largest randomized cardiovascular outcomes trial of TRT to date. Published in the New England Journal of Medicine in 2023, TRAVERSE found that testosterone replacement was non-inferior to placebo for major adverse cardiovascular events (MACE) over a mean follow-up of 33 months [9].

Specifically, MACE occurred in 7.0% of the testosterone group versus 7.3% in the placebo group (hazard ratio 0.96; 95% CI 0.78 to 1.17; P<0.001 for non-inferiority). This result led the FDA to revise labeling language in 2024, softening the cardiovascular warning while retaining the requirement to monitor.

Atrial fibrillation occurred more frequently in the testosterone arm (3.5% vs. 2.4%), a finding that has not yet changed prescribing guidelines but warrants discussion with patients who have pre-existing arrhythmia risk [9].

Polycythemia Risk Remains Real

The TRAVERSE trial confirmed that hematocrit elevations are the most consistent adverse effect of TRT across formulations. Hematocrit above 54% occurred in 5.7% of testosterone-treated men versus 1.5% of placebo-treated men. Clinicians should treat this as a real risk, not a theoretical footnote.

Fertility Preservation and TRT

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis, reducing intratesticular testosterone and shutting down spermatogenesis. For men who want future biological children, this is a critical pre-treatment conversation.

The American Society for Reproductive Medicine (ASRM) recommends sperm banking before initiating TRT for any man who has not completed family building [10]. Recovery of spermatogenesis after TRT cessation is not guaranteed and may take 6 to 18 months, with some men experiencing permanent azoospermia.

Alternative strategies include:

• Clomiphene citrate (50 mg every other day): Stimulates endogenous testosterone production without suppressing spermatogenesis.
• Human chorionic gonadotropin (hCG): Maintains intratesticular testosterone; often co-administered with TRT in fertility-preservation protocols.

What "Open About HRT Use" Actually Means Clinically

When a public figure says they use TRT, they are conveying a rough category, not a precise protocol. The phrase covers an enormous range of clinical scenarios: doses from 50 mg to 200 mg weekly, frequency from daily gel application to quarterly pellet implants, with or without ancillary agents like anastrozole to control estradiol, and with or without hCG.

Why Protocol Details Matter for Listeners

A 52-year-old man with a serum testosterone of 280 ng/dL and classic symptoms of hypogonadism has a clear clinical indication for TRT. A 38-year-old man with a testosterone of 410 ng/dL who is unhappy with his energy levels does not, by current guidelines, meet the diagnostic threshold [5].

Celebrity disclosure normalizes treatment, which can be beneficial. It can also prompt men who fall outside the diagnostic window to seek prescriptions from concierge clinics willing to treat by symptom profile alone, bypassing the two-test requirement. That practice is outside guideline-concordant care.

The Endocrine Society's Position

The Endocrine Society's 2018 guideline states: "We suggest against starting testosterone therapy in patients who are planning fertility in the near term, have uncontrolled heart failure, have a recent history of a cardiovascular event (within the past 6 months), or have an elevated hematocrit" [5]. This is a firm contraindication list, not a list of preferences.

Telehealth TRT Platforms: Disclosure Obligations and Patient Rights

The rapid growth of telehealth TRT prescribing has created a new category of legal obligation: direct-to-consumer marketing of prescription testosterone. Companies advertising TRT services must comply with FDA regulations governing prescription drug advertising (21 CFR Part 202), which require fair balance presentation of risks alongside benefits [7].

What Patients Should Confirm Before Starting

Patients using telehealth platforms for TRT should verify the following before their first prescription:

1. The prescribing clinician holds an active, unrestricted license in the patient's state.
2. The platform has collected two separate fasting morning testosterone measurements before prescribing.
3. A hematocrit baseline has been established.
4. The prescription is for an FDA-approved formulation, not a compounded product unless there is a specific documented rationale.
5. A monitoring schedule has been communicated in writing.

Compounded testosterone preparations exist outside FDA approval pathways. The FDA's guidance on compounding (503A and 503B regulations) permits pharmacy compounding under specific conditions, but patients should understand they are accepting reduced regulatory oversight [7].

State-Level Prescribing Rules

State medical boards may impose additional requirements. Texas, for instance, requires an in-person evaluation before a controlled substance (testosterone is Schedule III) can be prescribed in most circumstances, though telemedicine exceptions were expanded post-2020. Patients should confirm their state's rules directly with the prescribing platform.

Practical Considerations for Men Thinking About TRT

A celebrity's disclosure is a conversation starter, not a clinical referral. Men who are interested in TRT should follow a defined clinical pathway rather than simply contacting the nearest telehealth clinic after hearing a podcast mention.

Step One: Confirm Symptoms Are Present

The Androgen Deficiency in Aging Males (ADAM) questionnaire, validated in The Journal of Urology (Morley et al., 2000), screens for low testosterone symptoms with a sensitivity of 88% [11]. Answering yes to questions 1 or 7 (low libido or lack of energy) plus three additional questions constitutes a positive screen and warrants lab work.

Step Two: Get Two Morning Labs

Total testosterone, free testosterone, LH, FSH, complete blood count, and a comprehensive metabolic panel represent a reasonable baseline panel. Labs should be drawn between 7 and 10 a.m. Because testosterone follows a diurnal rhythm with peak levels in the morning [5].

Step Three: Find a Clinician Who Monitors

The single most important variable in TRT safety is consistent monitoring. Hematocrit, PSA, and testosterone levels must be checked at 3-month intervals for the first year, then adjusted to 6-month or annual intervals based on stability. Any clinician unwilling to commit to this schedule is not practicing guideline-concordant care.

Men with a serum total testosterone confirmed below 300 ng/dL on two separate morning draws, combined with at least three symptoms of hypogonadism, meet the diagnostic threshold and can begin a monitored trial of TRT. Labs should be rechecked at the 3-month mark with a trough draw taken immediately before the next scheduled injection.